Therapy options for patients with hepatocellular carcinoma (HCC), including a newly approved therapy for a subpopulation of patient.
Liver, Gallbladder, and Biliary Tract Cancers
Previous laboratory research along with phase I and II trials suggested the combination of doxorubicin and sorafenib could offer improved outcomes in advanced hepatocellular cancer.
A new phase 1a/b study examined a total of 49 patients with solid tumors, including 34 with ovarian, fallopian tube, or primary peritoneal cancer, treated with a combination of the PARP 1/2 inhibitor pamiparib and the anti-PD-1 monoclonal antibody tislelizumab in several dose escalation cohorts.
Researchers assessed patients with biliary tract cancer (BTC) who underwent ctDNA testing by means of a clinically available assay and analyzed samples using a 73-gene panel.
A new trial investigated the efficacy of XELOX vs GEMOX as first-line therapy for advanced biliary tract cancers.
An analysis found that tumor response as assessed using modified RECIST criteria is an independent predictor of overall survival in hepatocellular carcinoma patients.
Researchers tested the combination of dabrafenib and trametinib in a phase II trial of patients with biliary tract cancer and BRAF V600E mutations.
Recurrence risk was greater in sarcopenic patients, and greater alpha-fetoprotein and microvascular invasion were independent risk factors.
Patients with alcohol-related HCC had worse OS than other HCC patients, mainly due to poorer liver function and more unfavorable tumor characteristics at diagnosis.
The FDA has granted accelerated approval to nivolumab (Opdivo) for the treatment of patients with hepatocellular carcinoma who have previously received sorafenib.